Operating Income: The income after operating expenses.
Rigel Pharmaceuticals, Inc. (RIGL) had Operating Income of $17.11M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$80.89M |
|
$13.19M |
|
$10.78M |
|
$70.11M |
|
$63.78M |
|
|
Operating Income |
$17.11M |
$0.30M |
|
$17.41M |
|
$17.41M |
|
$13.19M |
|
$13.19M |
|
$13.19M |
|
$13.19M |
|
$17.11M |
|
$18.86M |
|
18.71M |
|
20.44M |
|
$0.70 |
|
$0.65 |
|
| Balance Sheet Financials | |
$188.52M |
|
-- |
|
$335.35M |
|
$523.88M |
|
$78.77M |
|
-- |
|
-- |
|
$78.77M |
|
$445.11M |
|
$350.52M |
|
$445.11M |
|
18.83M |
|
| Cash Flow Statement Financials | |
$67.94M |
|
$-8.97M |
|
$-52.91M |
|
$40.64M |
|
$46.70M |
|
$6.07M |
|
$15.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.39 |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
86.67% |
|
21.15% |
|
21.15% |
|
-- |
|
21.52% |
|
16.30% |
|
$67.94M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.68 |
|
1.43 |
|
62.82 |
|
2.96% |
|
3.76% |
|
2.52% |
|
2.96% |
|
$23.64 |
|
$3.32 |
|
$3.32 |
|